http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013522377-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D519-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-423 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4188 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 |
| filingDate | 2011-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2013522377-A |
| titleOfInvention | Analogs for treating or preventing flavivirus infection |
| abstract | A compound represented by formula I or a pharmaceutically acceptable salt thereof, wherein A, B, B ′, X, Y, R 1 , R 2 , R 2 ′, R 3 , R 3 ′, R 4 , R 4 ′, R 5, R 5 ′ m, n, or p are as defined herein. These compounds or pharmaceutically acceptable salts thereof are useful for treating flaviviridae viral infections. In another embodiment, the compound of the invention and one or more additional agents (viral serine protease inhibitor, viral polymerase inhibitor, viral helicase inhibitor, immunomodulator, antioxidant, antibacterial agent, therapeutic vaccine, hepatoprotectant, A combination comprising an antisense agent, an inhibitor of HCV NS2 / 3 protease, and an inhibitor of an internal ribosome entry site (IRES) is provided. |
| priorityDate | 2010-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 411.